Baldini L, Guffanti A, Cro L, Fracchiolla N S, Colombi M, Motta M, Maiolo A T, Neri A
Laboratorio di Ematologia Sperimentale e Genetica Molecolare, Istituto di Scienze Mediche dell'Università, Ospedale Maggiore IRCCS, Milano, Italy.
Br J Haematol. 1997 Nov;99(2):375-8. doi: 10.1046/j.1365-2141.1997.3973215.x.
We have recently reported a series of 15 non-villous splenic marginal zone lymphoma patients, six of whom showed p53 mutations (40%). This molecular alteration did not correlate with any particular clinico-pathologic feature at diagnosis. After a median follow-up of 56 months, four cases evolved into aggressive fatal non-Hodgkin's lymphoma (NHL) and two had refractory progressive disease; interestingly, p53 mutations were demonstrated in five of these patients at diagnosis. As the patients with wild-type p53 presented responsive or indolent disease, this genetic alteration may be an early marker of aggressive transformation or refractoriness. p53 evaluation at diagnosis could be advisable in this particular subset of NHL.
我们最近报告了一组15例非绒毛状脾边缘区淋巴瘤患者，其中6例显示p53突变（40%）。这种分子改变与诊断时的任何特定临床病理特征均无关联。中位随访56个月后，4例进展为侵袭性致命性非霍奇金淋巴瘤（NHL），2例患有难治性进展性疾病；有趣的是，这些患者中有5例在诊断时被证实存在p53突变。由于野生型p53患者表现出反应性或惰性疾病，这种基因改变可能是侵袭性转化或难治性的早期标志物。对于这一特定亚型的NHL，诊断时进行p53评估可能是可取的。
